Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion

• Recent onset (\< 6 months), non-ischemic CRVO (defined as association of documented retinal hemorrhage in all 4 quadrants of the retina with dilated veins) in patients who have not received treatment for their condition (e.g., no periocular depot or intraocular treatment [including corticosteroid and anti-VEGF], systemic corticosteroids or laser nor hemodilution).
• Retinal thickness measured by Stratus OCT > 250µm in the central subfield of study eye at baseline.
• BCVA score (measured by the ETDRS chart between 5 letters (20/800 Snellen equivalent) and 65 letters (20/50) in the study eye at baseline.
• Media clarity, pupillary dilation and participant cooperation sufficient for adequate fundus photographs.
• Females of childbearing potential using adequate birth control at Day 0 until study completion.
• Patient able (in the opinion of the investigator) and willing to return for all scheduled visits and assessments.
• Ability to read, understand and willingness to provide informed consent.

Exclusion Criteria:

• Rubeosis iridis or neovascular glaucoma at baseline.
• Preretinal neovascularisation at baseline.
• Ischemic CRVO, defined by more than 10 disc area of non-perfusion on fluorescein angiography at baseline.
• Any grade of diabetic retinopathy.
• Other eye condition that could contribute to macular edema or cause retinal vascular changes (including vitreomacular traction, uveitis and inflammatory disease, etc).
• Patients who have received treatment for their condition (e.g., no periocular depot or intraocular treatment [including corticosteroid and anti-VEGF], systemic corticosteroids or laser nor hemodilution).
• Ocular surgery (including cataract extraction, scleral buckle, etc.) and/or YAG capsulotomy within 3 months preceding treatment date or anticipated within the 3 months following treatment administration.
• Poorly controlled ocular hypertension and/or glaucoma (IOP greater than 25 mmHg despite maximal therapy).
• History of pars plana vitrectomy.
• Aphakia or anterior chamber intraocular lens.
• Presence of visible sclera thinning or ectasia.
• Presence of substantial cataract or other media opacity that, in the opinion of the investigator, is likely to interfere with visualization of the fundus or completion of study measurements.
• Any active ocular or peri-ocular infection (including conjunctivitis, chalazion or significant blepharitis).